News

This is the first of two phase I/II trials to be initiated. The second trial will be conducted in Europe and is likely to be initiated in the

In this study, patients who met the relevant criteria (either newly diagnosed or patients who have relapsed) for both insomnia and major depressive disorder (MDD), were randomized to

Forbes announced revenue guidance of C$21 to C$22 million for fiscal 2005 for the period ending December 31, 2005. This anticipated revenue represents a minimum 20% growth versus

The Vaccine Research Center (VRC) will utilize GenVec’s proprietary technologies for vaccine development, including its production cell line, 293-ORF6, to design and test next generation vaccines to optimize

The special protocol assessment (SPA) from the FDA documents agreement on the protocol under which Avanir will conduct and analyze the data from a pivotal trial evaluating the

The study is being conducted under an investigational new drug (IND) application that Memory Pharmaceuticals filed with the FDA in mid-November 2004. The safety and tolerability study is

Biovail’s new drug application (NDA) for this formulation was accepted for review by the FDA in May 2004. The approvable letter involves the resolution of labeling issues only,

In October 2004, the UK Medicines and Healthcare products Regulatory Agency (MHRA) suspended Chiron’s manufacturer’s license for the Fluvirin influenza vaccine at the Liverpool production site. Following the

The company’s consumer medicines businesses in Japan, China, Latin America Europe, Middle East and Africa are not included in this divestiture. Bristol-Myers Squibb’s primary consumer medicine brands in